Next Article in Journal / Special Issue
Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation
Previous Article in Journal
Immunohistochemistry of Programmed Cell Death in Archival Human Pathology Specimens
Previous Article in Special Issue
Increased Level of IFN-γ and IL-4 Spot-Forming Cells on ELISPOT Assay as Biomarkers for Acute Graft-Versus-Host Disease and Concurrent Infections
Cells 2012, 1(2), 89-99; doi:10.3390/cells1020089
Review

Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma

1
, 2
 and 3,*
Received: 14 March 2012; in revised form: 11 April 2012 / Accepted: 17 April 2012 / Published: 7 May 2012
(This article belongs to the Special Issue ELISPOT Research)
View Full-Text   |   Download PDF [200 KB, uploaded 7 May 2012]
Abstract: Mycobacterium tuberculosis (MTB) is a global heath epidemic, its threat amplified by HIV infection and the emergence of multidrug-resistant tuberculosis (MDR-TB). Interferon (IFN)-gamma release assays (IGRAs) have improved the accuracy of detection of MTB exposure in some subject groups as compared to the Tuberculin Skin Test (TST). However, as IFN-gamma is produced by both fully rested and more recently activated populations of memory T cells, it is not surprising that the measurement of this cytokine alone cannot accurately distinguish Latent TB Infected (LTBI) subjects from those with active (infectious) disease. Accurate and rapid diagnosis of infectious individuals would allow medication to be properly allocated and other actions taken to more effectively curtail MTB spread. Analysis of multi-cytokine profiles ex vivo after stimulation of PBMCs from LTBI and active MTB subjects indicate the real possibility of successfully discerning these two disease states within 24 hours of a subject’s blood draw. Due to the unparalleled sensitivity, low cost, and ease of use of Elispot assays, we propose that via a multiplex Elispot platform the accurate distinction of LTBI from active MTB-infected individuals is within reach.
Keywords: mycobacterium tuberculosis; Elispot; polyfunctional T cell; IFN-gamma; LTBI; active MTB mycobacterium tuberculosis; Elispot; polyfunctional T cell; IFN-gamma; LTBI; active MTB
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Tincati, C.; Cappione III, A.J.; Snyder-Cappione, J.E. Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma. Cells 2012, 1, 89-99.

AMA Style

Tincati C, Cappione III AJ, Snyder-Cappione JE. Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma. Cells. 2012; 1(2):89-99.

Chicago/Turabian Style

Tincati, Camilla; Cappione III, Amedeo J.; Snyder-Cappione, Jennifer E. 2012. "Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot Assays: Looking Beyond Interferon-gamma." Cells 1, no. 2: 89-99.


Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert